Effects of aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke: The AGgrenox versus Aspirin Therapy Evaluation (AGATE) biomarker substudy

Victor Serebruany, Yanti Sani, Christian Eisert, Alex Schevchuck, Alan Fong, Dan Hanley

Research output: Contribution to journalArticlepeer-review

Abstract

Plasma endothelial nitric oxide synthase (eNOS), and oxidised low-density lipoproteins (oxLDL) are established biomarkers of atherosclerosis. We defined the time course and magnitude of changes of plasma eNOS and oxLDL after Aggrenox or aspirin in post-stroke patients. Baseline pretreatment eNOS levels were significantly diminished (110 ± 66pg/ml vs. 374 ± 88 pg/ml, p=0.0001), while oxLDL was twice higher (58 ± 9 mg/l vs. 23 ± 7 mg/l, p=0.004) in post-stroke survivors when compared to controls. Both Aggrenox and aspirin similarly increased plasma eNOS activity. However, oxLDL levels were static after aspirin, but inhibited late after Aggrenox. In the small randomised study, both aspirin and Aggrenox produced fast and sustained recovery of plasma eNOS levels, while only therapy with Aggrenox was associated with oxLDL inhibition late in the trial.

Original languageEnglish (US)
Pages (from-to)81-87
Number of pages7
JournalThrombosis and Haemostasis
Volume105
Issue number1
DOIs
StatePublished - Jan 1 2011

Keywords

  • Aggrenox
  • Aspirin
  • Nitric oxide
  • Oxidised LDL
  • Stroke

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Effects of aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke: The AGgrenox versus Aspirin Therapy Evaluation (AGATE) biomarker substudy'. Together they form a unique fingerprint.

Cite this